BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17244226)

  • 21. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravitreal bevacizumab (Avastin) in idiopathic retinitis, vasculitis, aneurysms and neuroretinitis.
    Akesbi J; Brousseaud FX; Adam R; Rodallec T; Nordmann JP
    Acta Ophthalmol; 2010 Mar; 88(2):e40-1. PubMed ID: 19508455
    [No Abstract]   [Full Text] [Related]  

  • 23. Early intravitreal bevacizumab for non-ischaemic central retinal vein occlusion.
    Rensch F; Jonas JB; Spandau UH
    Acta Ophthalmol; 2009 Feb; 87(1):77-81. PubMed ID: 18937800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Herpetic epithelial keratitis after intravitreal injection of bevacizumab (avastin).
    Khalili MR; Mehdizadeh M; Mehryar M
    Cornea; 2009 Apr; 28(3):360-1. PubMed ID: 19387245
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients.
    Pedersen KB; Sjølie AK; Møller F
    Acta Ophthalmol; 2009 Nov; 87(7):714-9. PubMed ID: 19094171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravitreal bevacizumab injection for central serous chorioretinopathy.
    Nowroozzadeh MH
    Retina; 2010 Sep; 30(8):1322-3; author reply 1323. PubMed ID: 20827148
    [No Abstract]   [Full Text] [Related]  

  • 27. Intravitreal bevacizumab injection for central serous chorioretinopathy.
    Chhablani JK; Narayanan R
    Retina; 2010 Sep; 30(8):1323-24; author reply 1324. PubMed ID: 20661171
    [No Abstract]   [Full Text] [Related]  

  • 28. Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes.
    Inan UU; Avci B; Kusbeci T; Kaderli B; Avci R; Temel SG
    Invest Ophthalmol Vis Sci; 2007 Apr; 48(4):1773-81. PubMed ID: 17389511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo corneal endothelial safety of intracameral bevacizumab and effect in neovascular glaucoma combined with Ahmed valve implantation.
    Shin JP; Lee JW; Sohn BJ; Kim HK; Kim SY
    J Glaucoma; 2009; 18(8):589-94. PubMed ID: 19826387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravitreal bevacizumab for branch retinal vein occlusion.
    Spandau U; Wickenhäuser A; Rensch F; Jonas J
    Acta Ophthalmol Scand; 2007 Feb; 85(1):118-9. PubMed ID: 17244225
    [No Abstract]   [Full Text] [Related]  

  • 31. Bevacizumab local complications.
    Gordon-Angelozzi M; Velez-Montoya R; Fromow-Guerra J; García-Aguirre G; Guerrero-Naranjo JL; Quiroz-Mercado H; Morales-Cantón V
    Ophthalmology; 2009 Nov; 116(11):2264.e1-3. PubMed ID: 19883862
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy.
    Hoang QV; Tsuang AJ; Gelman R; Mendonca LS; Della Torre KE; Jung JJ; Freund KB
    Retina; 2013 Jan; 33(1):179-87. PubMed ID: 22990314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isolated sixth nerve palsy after intravitreal bevacizumab injection.
    Cakmak HB; Toklu Y; Yorgun MA; Simşek S
    Strabismus; 2010 Mar; 18(1):18-20. PubMed ID: 20230202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surgical outcomes of intravitreal bevacizumab and guarded filtration surgery in neovascular glaucoma.
    Fakhraie G; Katz LJ; Prasad A; Eslami Y; Sabour S; Zarei R; Moghimi S
    J Glaucoma; 2010 Mar; 19(3):212-8. PubMed ID: 19593201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study.
    Chen CY; Wong TY; Heriot WJ
    Am J Ophthalmol; 2007 Mar; 143(3):510-2. PubMed ID: 17317398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Controversies in the treatment of wet age-related macular degeneration.
    Moreno SF; Paloma JB
    Am J Ophthalmol; 2008 May; 145(5):937; author reply 938. PubMed ID: 18435977
    [No Abstract]   [Full Text] [Related]  

  • 37. Intravitreal bevacizumab for retinal capillary haemangioma: longterm results.
    Ach T; Thiemeyer D; Hoeh AE; Schaal KB; Dithmar S
    Acta Ophthalmol; 2010 Jun; 88(4):e137-8. PubMed ID: 19681788
    [No Abstract]   [Full Text] [Related]  

  • 38. Angiographic changes after bevacizumab.
    Ikuno Y; Soga K; Wakabayashi T; Gomi F
    Ophthalmology; 2009 Nov; 116(11):2263.e1. PubMed ID: 19883861
    [No Abstract]   [Full Text] [Related]  

  • 39. Early loss of pregnancy after intravitreal bevacizumab injection.
    Petrou P; Georgalas I; Giavaras G; Anastasiou E; Ntana Z; Petrou C
    Acta Ophthalmol; 2010 Jun; 88(4):e136. PubMed ID: 19740128
    [No Abstract]   [Full Text] [Related]  

  • 40. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.
    Kumar V; Ghosh B; Raina UK; Goel N
    Am J Ophthalmol; 2008 Dec; 146(6):974; author reply 974-5. PubMed ID: 19027427
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.